Aliskiren-induced QT interval prolongation.
Aliskiren gained FDA approval for the treatment of hypertension in 2007. It is the first approved pharmaceutical to manage hypertension by direct renin inhibition. With the introduction of novel drugs and mechanisms of action comes the challenge of monitoring for new unreported adverse events. The side effect profile for aliskiren has not yet been fully described. We describe the first apparent report of aliskiren-induced QT prolongation resulting in torsades de pointes.
Peitz
Gregory J
GJ
Pharmacy Department, Sanford USD Medical Center, Sioux Falls, SD 57117-5039, USA. peitzg@sanfordhealth.org
Malesker
Mark A
MA
Sojka
S George
SG
D000368:Aged; D000577:Amides / Q000009:adverse effects*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects*; D005260:Female; D005650:Fumarates / Q000009:adverse effects*; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced*; D013015:Sotalol / Q000009:adverse effects
D000577:Amides; D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D005650:Fumarates; C446481:aliskiren; D013015:Sotalol